

2-28-2023

The Role of Telehealth in Enabling Sustainable Innovation and Circular Economies in Health

Dimitrios Kalogeropoulos

Paul Barach

Follow this and additional works at: <https://jdc.jefferson.edu/healthpolicyfaculty>

 Part of the [Public Health Commons](#), and the [Telemedicine Commons](#)

[Let us know how access to this document benefits you](#)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in College of Population Health Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

The Role of Telehealth in Enabling Sustainable Innovation and Circular Economies in Health

Dimitrios Kalogeropoulos^{1,2,3,*}  ; Paul Barach^{4,5} 

¹UCL Global Business School for Health, London, UK; ²Edison™ Accelerator; London, UK; ³IEEE Standards Association, Healthcare and Life Sciences Practice, New York City, New York, USA; ⁴Thomas Jefferson College of Population Health, Philadelphia, Pennsylvania, USA; ⁵Sigmund Freud University, Vienna, Austria

*Correspondence: Dimitrios Kalogeropoulos, Email: d.kalogeropoulos@ieee.org

Keywords: artificial intelligence (AI), circular economy, data asymmetry, digital health, health innovation ecosystems telehealth, evaluation, value-based care

Abstract

Digital health interventions, including the use of telehealth augmented by artificial intelligence (AI), support an increasingly broad range of improvement goals for prevention and treatment. Limitations obstructing the many digital benefits of the targeted healthcare innovations from reaching their full potential include the lack of robust usability and user-centered design, nimble regulatory policy, and lack of adequate high-quality evidence and methodologies to evaluate the performance generalization and clinical robustness. We explore health innovation using different value systems and solutions proposed to overcome the fundamental limitations arising in the data value system. We propose a new telehealth paradigm and incorporate intervention designs, which combine clinical innovation with innovation in data resource development. Machine learning and AI have the potential to enable circular economies for digital and health innovation, in which sustainable solutions can be offered within a data-enabled collaborative and shared digital ecosystem. Alignment of industry standards, adjustments to regulatory policies, and the embrace of new governance models for telehealth-based innovation are essential for this new approach for health innovation scaling, clinical adoption, and social innovation.

Received: January 11, 2023; Accepted: February 14, 2023; Published: February 28, 2023

The world of healthcare was compelled in 2020 to adapt quickly when faced with a global pandemic crisis. Many countries adapted with telehealth and shifted to the widespread provision of healthcare utilizing telephone and video consults or remote patient management and triaging. These were important, as in-person patient visits became limited and medical offices were forced to close or maintain social distancing.^{1,2}

Telehealth extends beyond the doctor–patient relationship, defined as the delivery and facilitation of health and health-related services. Examples include medical care, provider and patient education, health information services, and self-care via telecommunications and digital communication technologies.³ Healthcare provision through telehealth includes telephone support, messaging, smartphone applications, internet-based approaches, and remote monitoring.⁴ There is a distinction between the terms telehealth and telemedicine (TM), with TM

considered a subset of telehealth, and strictly referring to the provision of clinical healthcare services using digital-based communication technologies. Aspects of data capture during remote TM care are significantly limited. The transition to telehealth is key for the adoption, scaling, clinical robustness, and sustainability of digital health interventions (DHIs). This transition is needed to generate evidence in support of safe use, integration of DHIs and tools into clinical practice and to support patient care and outcome improvements.

Digital health interventions support a broad range of first-order improvement results, including the discovery of new knowledge on disease and treatments using artificial intelligence (AI), real-world evidence (RWE) for health technology assessments and clinical trials, better informed clinical and policy decisions, patient engagement and continuity-of-care, expanding access to care, and transformation of healthcare.^{5,6} Digital phenotyping is an emerging DHI

paradigm that relies on smartphones and wearables to support the continuity of care and improve scalability.^{7–15}

Multiple reviews have examined the positive evidence for effectiveness, cost-effectiveness, patient perceptions, and effects of telehealth on mortality. However, several ongoing concerns remain.^{16–18} An often-overlooked aspect when examining telehealth's role in digital innovation is the social value created by DHIs, which can be leveraged to deliver social innovation. Social innovation can be understood as long-lasting changes through scaling and adoption. The changes include the organization and functions of health systems, governance transformations, innovation in care models, and the re-organization of care processes, which might include institutional and system transformations.¹⁹ Social innovation initiated by DHIs can impact social values such as creating a trusting and trusted health system.²⁰

The integration of the DHIs mitigates the frequently small telehealth project results that are limited in time or region and often do not translate into sustainable changes in the organization and function of health systems.²¹

Social Value of Digital Health Interventions

Transformational changes can be achieved in population health through DHIs that are designed, developed, and scaled with social value and social innovation as endpoints. Approaching health innovation from the perspective of social value in addition to clinical and economic value can help industry and regulators map the true complexities involved in achieving the quadruple aim. Four interdependent goals consist of (1) enhancing patient experience and safety, (2) improving population health, (3) reducing costs and preventing loss of revenue, and (4) improving wellness and satisfaction of healthcare workers.²² Restoring the balance in data ecosystems with DHI scaling and robust clinical practice integration, can help prevent data asymmetries,²³ and enable patient-centered collaboration models, leveraging cooperation and continuity between DHIs towards circular economies in health.^{24–26}

A circular economy is based on three principles, driven by design: eliminate waste and pollution, keep products and materials in use, and regenerate natural systems. A circular economy aims to drive sustainability, equity, and digital inclusion,²⁷ translating to further transformation cycles and resilience. Accelerating the use of AI for knowledge discovery is needed^{28–35} to encourage and foster cooperation and implement industry standards that translate knowledge discovery into readily available, high-quality service interventions.

Standards and practices in healthcare must be reevaluated to enable intelligent transformation cycles. By applying knowledge supported by evidence that fuels these transformation cycles,³⁶ the data value challenge must be addressed.^{37,38}

Designing and delivering business and social value through health innovation technologies, such as AI, is a challenge.^{39,40} The challenge of sustaining and scaling value manifests in the gaps between AI investments supporting telehealth and the variable and poor performance generated from clinical trials, clinical practice integration, and clinical robustness.^{41–43} Inclusion and equity are critical for global-scale social innovation initiatives to succeed.⁴⁴ Failure to deliver inclusive digital development for the benefit of patients, communities, providers, or innovators, undermines applications and sustainability of AI discovery.⁴⁵

Often it is difficult to distinguish which of the value systems contributes more to the needs of patients, thus making scaling more complex. Consider for example an AI-backed referral device or application for patients with congestive heart failure, which besides offering support to the care continuum and patient pathway selection can also capture reliable and valuable continuity-of-care data. These data are required to transition clinical reasoning to clinical coherence, and precision medicine, and to support meaningful, scalable, and sustainable DHI.^{46–48}

Medical Device Development Challenges

From a medical device development perspective, value demonstration and scaling are about proving robust performance in improving patient outcomes under real-world conditions. Typically, this requires costly randomized controlled trials or a new pragmatic clinical trials ecosystem capability, which is challenging as few have the knowledge or the experience to run large trials.⁴⁹ Evaluating telehealth clinical robustness often falls below accepted evidence thresholds for improvement due to the lack of proper expertise and investments. A strategy that might work to overcome this bottleneck is to approach innovation from the perspective of a clinical-economic evaluation,^{40,50} which can facilitate the introduction of new devices into clinical practice by proving efficiency improvements at an embryonic phase of digital transformation.³⁹ This approach can simplify things if new innovations demonstrate social, economic, and business values before they impact clinical practice value.

Data Value Predicament in Health Innovation

Data value is a circular dependency between DHIs and social innovation, which aims to deliver inclusive data. Addressing this data value predicament in health innovation offers flexibility within innovation ecosystems, to help close the implementational gaps between design and delivery. Telehealth-driven innovation can deliver a better data ecosystem. However, current regulatory policy paradigms that focus on DHIs as standalone medical devices do not facilitate the proposed data-coupled approach to expand access to care and strengthen continuity and

patient-centric models. Efforts to regulate AI prescriptively are both celebrated and vilified,⁵¹ perceived as decelerating progress until we better understand the true impact of these technologies and prepare health systems to support innovative ideas. While standalone medical device regulation aims to distribute liability more evenly across the stakeholder spectrum and thus increase the regulatory impact on healthcare outcomes,^{52,53} it often deflects attention from the core issues of the liability process, for example, for a telehealth device designed to triage patients, to an encounter with outpatient clinics, to hospitalization, and post-discharge digital care. The current paradigm fails to promote trust and the safe development and integration of DHIs.^{54–56}

Device-centered regulatory policies neither address access-to-care efficiencies nor reverse the course of increased health disparities. Instead, they often lead to new digital inequities for vulnerable groups.^{57,58,59} Digital health interventions delivered in the current policy when they exacerbate existing inequities, can lead policymakers to more regulatory control and a spiral of deceleration in the digital health economy and health innovation.

Real-world evidence,^{33,39} is shaped into an engineered ‘ground truth’, artificially augmented and synthesized^{60,61} to simulate temporal context and longitude⁶² – conditions necessary to measure performance against desired patient outcomes. This approach is not sustainable, as it is both resource-intensive and fails the tests of explainability and reproducibility.⁶³ Trial designs based on RWE have the potential to increase scaling efficiency and reduce the cost of innovation.⁶⁴ Capturing and transferring value along the innovation supply chain with data sharing is key to delivering trust and performance.

Importance of Regulatory Sandboxes

Regulatory sandboxes (a published regulatory approach that allows testing of innovations under a regulator’s oversight) enable accelerated learning about opportunities and risks that a particular innovation carries and develop the right regulatory environment. Regulatory sandboxes test innovative technologies, products, services, or approaches, which are not compliant with the existing legal and regulatory framework.⁶⁵ Policies such as regulatory sandboxes can help with controlled acceleration and scaling. Sandboxes require instruments that provide legal flexibility, for example, in the form of experimentation clauses (i.e. temporary rules allowing experiments to be conducted). Regulatory sandboxes may not, however, resolve the obstacles encountered in scaling innovations because of the poor design of data ecosystems and lack of appreciation of the complex elements involved in the innovation. Scaling AI will continue to be challenging until information sharing becomes a standard of care.

The Innovator’s Predicament

There will likely be little improvement in the safety and quality of healthcare systems without resolving the data value predicament. New value margins can be created and shared equitably by effectively addressing the data value predicament – including equity and inclusion in data samples used for clinical and policy decisions and facilitating connected innovation.

Supporting the Workforce of the Future

Hospitals and health systems continue to face healthcare workforce and staffing shortages, with job vacancies of specialized nursing personnel increasing by as much as 30% between 2019 and 2022. Insufficient resources for training, poor work-life balance, utilization inefficiencies, and scope of practice limitations on healthcare providers contribute to shortages and provider burnout.⁶⁶

Technology can profoundly influence work processes – mitigating, for example, the burdens associated with redundant paperwork or low clinical value tasks. This depends on integrating and streamlining voluminous regulations, and mitigating the increasingly apparent role ambiguity, in part due to siloed DHIs. Abundant evidence suggests that doctors waste over two-thirds of their time doing paperwork causing much frustration to patients and staff, waste, and non-added-value.^{67,68}

The array of regulations that govern healthcare overwhelms people in the industry. Almost every aspect of the field is overseen by one regulatory body or another, and sometimes by several. Healthcare professionals feel that they spend more time complying with rules that direct their work than doing the work itself.^{69,70} The growing shift of tasks done by various members of the healthcare team, and the relaxation of licensure and credentialing during the COVID-19 pandemic are causing much confusion and misalignment given ambiguous role clarity. This role clarity is a key facet of interprofessional collaboration, which is crucial for effective, safe, and reliable interprofessional team functioning and exceptional service.^{71,72}

Technology has the potential to enhance throughput and reduce costs.⁷³ There will likely be improvements in skill/task alignment (working at the top of one’s license). Teamwork will be prioritized, and data analytics and data-driven decision-making, and workflow optimizations will become increasingly the norm.^{74,75} All this focus on labor arbitrage is built on the assumption that tasks can be easily sorted by licensure or training without sacrificing quality. This leads to an insidious equivalence being developed in which healthcare professionals are seen as potential substitutes for one another. Significant differences in training length and intensity are casually being washed away. Pandemic-inspired changes have greatly lessened these restrictions allowing more flexibility in which less trained people

are doing jobs of credentialed and highly trained providers. Time will tell if this innovation comes at the price of quality of patient care, industrial action, and burnout rates.⁷⁶

Well-designed telehealth platforms can enable better team coupling and data-driven awareness and mutual accountability towards the group's task – better servicing of patients. Real-time data analytics and transparency can help improve clinical workflow and rebuild team trust and encourage truth-telling by healthcare team members.

Limitations of the Regulatory Policy Paradigm for Telehealth

There are several challenges to the present regulatory policy approach for telehealth, which broadly ignore the domains and intersections of, the sciences of human factors, implementation science, improvement science, safety and risk management sciences, and more. Regulatory policy paradigms for telehealth do not provide recommendations for action. For example, regulators are concerned that the growth of telehealth will lead healthcare providers to only offer telehealth, thus reducing the available supply of providers physically located in given geography; out-of-state telehealth providers will 'come in' and take low acuity and private-pay patients/patient dollars away from local providers, which could cause them to close, move, or care for fewer patients as a percentage of total patients. Furthermore, out of state telehealth providers will operate outside of the local regulatory policy paradigm, thereby weakening state and local regulatory influence and oversight. This is especially true for behavioral health and pharmacy care, but can generally lead to problematic telehealth policy paradigms in, for example, requirements that telehealth providers have a physical office location (or see patients in person x times over x time period). None of these factors have been adequately addressed, despite their impact on the regulatory policy paradigm, and thereby the political-economic market in which telehealth and DHIs exist.

Discussion

The DHI market is driven by the current device-centered regulatory paradigm rather than access to a functioning data-driven innovation ecosystem. While the pandemic accelerated the demand for digital innovation and the inadequate means and policies to scale DHIs to social value demonstrations, the transfer of value and sustainability in the current innovation ecosystems continues to be compromised. This raises legitimate questions about value.⁷⁷

This calls for wide reform, nimble regulation, and sustained innovation to address the innovators and data value predicaments. A digital innovation acceleration superstructure that connects DHIs across the care continuum, comprising standards, aligned and enabling

telehealth-based governance and regulatory policies that can (1) enable data resource innovation, (2) address the pressing governance and transparency issues inhibiting DHIs from expanding into the space of community-health and public health, (3) lend structure to real-world data for trusted evidence, (4) provide a new pathway to radically different structures in delivery models, (5) reduce healthcare worker's workload, (6) improve outreach, engagement, and prevention at scale, all while (7) collecting structured data.

Health innovation interventions can impact healthcare and public health systems but only if they positively impact outcomes that matter to patients.⁷⁸ Examples include patient-reported health-related quality of life, symptom severity, satisfaction with care, resource utilization, hospitalizations, readmissions, and survival. Resource utilization is a measure of how much of the available resources one is currently using. It can help healthcare payors and executives to plan how to utilize resources more effectively in order to ensure that the organization is being as productive as possible.⁷⁹ Efficient organizations enhance the service, quality, and flow for patients in their interactions with the healthcare system. There are limited data investigating the impacts of telehealth on these outcome measures.⁷⁸ There are many good studies investigating in-person care, for example, heart and lung failure diseases such as myocardial ischemia, asthma, and more.⁸⁰

Digital health interventions are likely to succeed if they are developed directly and cooperatively in partnership with end-users – i.e. patients and front-line clinicians. The new telehealth paradigm for participatory, connected, and interactive innovation should address these needs. Telehealth can deliver the necessary data validation when coupled with the use of smart mobile devices, telehealth, or mHealth apps while enabling the integration of digital devices into a digital care continuum where they can be evaluated for clinical robustness with RWE.⁸¹

Telehealth should be considered a safe alternative to some traditional face-to-face medical procedures.⁸⁰ Given the trends in technological advances in the past decades, it is likely that healthcare reliance on telehealth will continue to grow. These findings can be utilized to guide policymakers and service evaluation.

Several key research questions remain unanswered. These include the need to evaluate the risks of different telehealth patient care interventions, utilize longitudinal and adaptive study designs, and with heterogeneous, diverse, and large sample sizes to follow up with participants. There is growing evidence for comparing in-person care to telehealth with favorable results, evaluating telehealth results using in-person care as the comparator or pre-telehealth care as the gold standard.⁴⁰ Ongoing and future audits must monitor the veracity of these assumptions and make that part of all external accreditation.

A longitudinal study design will allow researchers and health practitioners to ensure that the treatment options do not yield long-term unforeseen concerns. Finally, studies with an increased number of participants are encouraged for the results to be more generalizable. In the case of longitudinal studies of in-person care, the multi-factorial elements known to impact outcomes are known to suffer from a variety of biases.

Conclusions

Current evidence-generation systems of DHI require an overhaul. Embracing new value systems is important to reforming current regulatory shortcomings and fostering connected innovation acceleration. Further development of normative, legal, and regulatory frameworks is necessary to further systems medicine and translational precision medicine,⁸² promote broad adoption of common standards across healthcare modalities (whether digital or in-person) and sustain systems change to promote health innovation.⁸³

Solving these problems will require a focus on three key domains:

1. improving the integration of and access to high-quality data from traditional clinical trials, electronic health records, and personal devices and wearable sensors;
2. restructuring clinical research operations to support and incentivize the involvement of patients and front-line clinicians; and
3. articulating ethical constructs that enable responsible data sharing to support improved implementation (78)

Much needs to evolve regarding data ecosystems and the integration of RWE into existing clinical practice and gold standards of care. This is in contradistinction to regulating single devices at the atomized level. Despite the abundance of standards for the classification of clinical observations, there are not sufficient standards to evaluate the new telehealth paradigm. Appropriate standards must aim to support the integration of DHIs into a patient-centric continuum, to provide for connectivity and interaction among DHIs, and to enable the seamless transition of activity from one telehealth service to another. Creating incentives for integration and data sharing will be essential to achieve more timely and equitable improvement in health outcomes.

Funding Statement

No funding was provided in drafting this paper.

Financial and non-Financial Relationships and Activities

The authors confirm no relevant conflicts of interest.

Contributions

Both authors contributed to the research and writing of this article.

Acknowledgments

None

References

1. Wherton J, Shaw S, Papoutsi C, Seuren L, Greenhalgh T. Guidance on the introduction and use of video consultations during COVID-19: important lessons from qualitative research. *BMJ Leader* 2020; 4(3): 120–3. doi: 10.1136/leader-2020-000262
2. Tabacof L, Wood J, Mohammadi N, Link KE, Tosto-Mancuso, Dewil S, et al. Remote patient monitoring identifies the need for triage in patients with acute COVID-19 infection. *Telemed J E Health* 2022; 28(4): 495–500. doi: 10.1089/tmj.2021.0101.
3. Catalyst N. What is telehealth? *NEJM Catalyst* 2018; 4(1).
4. Salisbury C, O’Cathain A, Edwards L, Thomas C, Gaunt D, Hollinghurst S, et al. Effectiveness of an integrated telehealth service for patients with depression: a pragmatic randomised controlled trial of a complex intervention. *Lancet Psychiatry* 2016; 3(6): 515–25.
5. Davidson L, Boland MR. Towards deep phenotyping pregnancy: a systematic review on artificial intelligence and machine learning methods to improve pregnancy outcomes. *Brief Bioinform.* 2021; 22(5): bbaa369. doi: 10.1093/bib/bbaa369.
6. Verma A, Towfighi A, Brown A, Abhat A, Casillas A. Moving towards equity with digital health innovations for stroke care. *Stroke* 2022;53(3):689–97. doi: 10.1161/STROKEAHA.121.035307
7. Martinez-Martin N, Insel TR, Dagum P, Greely HT, Cho MK. Data mining for health: staking out the ethical territory of digital phenotyping. *npj Digital Med.* 2018; 1: 68. doi: 10.1038/s41746-018-0075-8
8. Milne R, Costa A, & Brenman N. Digital phenotyping and the (data) shadow of Alzheimer’s disease. *Big Data & Society.* 2022; 9(1). doi: 10.1177/20539517211070748
9. Bilal AM, Fransson E, Bränn E, Eriksson A, Zhong M, Gidén K, et al. Predicting perinatal health outcomes using smartphone-based digital phenotyping and machine learning in a prospective Swedish cohort (Mom2B): study protocol. *BMJ Open.* 2022; 12(4): e059033. doi: 10.1136/bmjopen-2021-059033
10. Engelmann L. Digital epidemiology, deep phenotyping and the enduring fantasy of pathological omniscience. *Big Data & Society.* 2022; 9(1). doi: 10.1177/20539517211066451
11. Tomićić A, Malešević A, Čartolovni A. Ethical, legal and social issues of digital phenotyping as a future solution for present-day challenges: A scoping review. *Sci Eng Ethics.* 2021; 28(1): 1. doi: 10.1007/s11948-021-00354-1
12. Huckvale K, Venkatesh S, Christensen H. Toward clinical digital phenotyping: a timely opportunity to consider purpose, quality, and safety. *NPJ Digit Med.* 2019; 2: 88. doi: 10.1038/s41746-019-0166-1
13. Torous J, Kiang MV, Lorme J, Onnela JP. New tools for new research in psychiatry: a scalable and customizable platform to empower data driven smartphone research. *JMIR Ment Health.* 2016; 3(2): e16. doi: 10.2196/mental.5165
14. Jayakumar P, Lin E, Galea V, Mathew AJ, Panda N, Vetter I, et al. Digital phenotyping and patient-generated health data for outcome measurement in surgical care: a scoping review. *J Pers Med.* 2020; 10(4): 282. doi: 10.3390/jpm10040282

15. Nguyen B, Ivanov M, Bhat V, Krishnan S. Digital phenotyping for classification of anxiety severity during COVID-19. *Front Digit Health*. 2022; 4: 877762. doi: 10.3389/fdgth.2022.877762
16. Snoswell CL, Chelberg G, De Guzman KR, Haydon HH, Thomas EE, Caffery LJ, et al. The clinical effectiveness of telehealth: a systematic review of meta-analyses from 2010 to 2019. *J Telemed Telecare*. 2021; 1357633X211022907. doi: 10.1177/1357633x211022907
17. Snoswell CL, Taylor ML, Comans TA, Smith AC, Gray LC, Caffery LJ. Determining if telehealth can reduce health system costs: scoping review. *J Med Internet Res*. 2020; 22(10): e17298. doi: 10.2196/17298
18. Snoswell CL, Stringer H, Taylor ML, Caffery LJ, Smith AC. An overview of the effect of telehealth on mortality: a systematic review of meta-analyses. *J Telemed Telecare*. 2021; 1357633X211023700. doi: 10.1177/1357633x211023700
19. Van Niekerk L, Manderson L, & Balabanova D. The application of social innovation in healthcare: a scoping review. *Infect Dis Poverty*. 2021; 10: 26. doi: 10.1186/s40249-021-00794-8
20. Whyte E, Olivier J. Social values and health systems in health policy and systems research: a mixed-method systematic review and evidence map. *Health Policy Plan*. 2020; 35(6): 735–51. doi: 10.1093/heapol/czaa038
21. Haring M, Freigang F, Amelung V, Gersch M. What can healthcare systems learn from looking at tensions in innovation processes? A systematic literature review. *BMC Health Serv Res*. 2022; 22: 1299. doi: 10.1186/s12913-022-08626-7
22. Wang A, Ahmed R, Ray J, Hughes P, Eric McCoy E, Marc A, et al. Supporting the quadruple aim using simulation and human factors during COVID-19 care. *Am J Med Qual*. 2021; 36(2): 73–83. doi: 10.1097/01.JMQ.0000735432.16289.d2
23. Verhulst S, Young A. Identifying and addressing data asymmetries so as to enable (better) science. *Front Big Data*. 2022; 5: 888384. doi: 10.3389/fdata.2022.888384
24. Final Terms of Reference of the Alliance for Transformative Action on Climate and Health (ATACH), World Health Organization Technical Document, 31 August 2022. Available from: <https://www.who.int/publications/m/item/atach-terms-of-reference> [cited 1 February 2023].
25. Communication from the commission to the European Parliament and the council, 2022 strategic foresight report – Twinning the green and digital transitions in the new geopolitical context. COM/2022/289 final. Available from: <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A52022D-C0289&qid=1658824364827> [cited 1 February 2023].
26. Coalition for Digital Environmental Sustainability (CODES). Action plan for a sustainable planet in the digital age (2022). Available from: <https://doi.org/10.5281/zenodo.6573509> [cited 1 February 2023].
27. Equity within digital health technology within the WHO European Region: a scoping review. World Health Organization, 21 December 2022, WHO/EURO:2022-6810-46576-67595. Available from: <https://www.who.int/europe/publications/i/item/WHO-EURO-2022-6810-46576-67595> [cited 1 February 2023].
28. Apweiler R, Beissbarth T, Berthold MR, Blüthgen N, Burmeister Y, Dammann O, et al. Whither systems medicine? *Exp Mol Med*. 2018; 50(3): e453. doi: 10.1038/emmm.2017.290.
29. Schleidgen S, Fernau S, Fleischer H, Schickhardt C, OBa AK, Winkler EC. Applying systems biology to biomedical research and health care: a précis definition of systems medicine. *BMC Health Serv Res*. 2017; 17(1): 761. doi: 10.1186/s12913-017-2688-z
30. Soenksen LR, Ma Y, Zeng C, Boussieux L, Carballo KV, Na L, et al. Integrated multimodal artificial intelligence framework for healthcare applications. *npj Digit Med*. 2022; 5: 149. doi: 10.1038/s41746-022-00689-4
31. Tian Q, Price ND, Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. *J Intern Med*. 2012; 271(2): 111–21. doi: 10.1111/j.1365-2796.2011.02498.x
32. Stahlberg EA, Abdel-Rahman M, Aguilar B, Asadpoure A, Beckman RA, Borkon LL, et al. Exploring approaches for predictive cancer patient digital twins: opportunities for collaboration and innovation. *Front Digit Health*. 2022; 4: 1007784. doi: 10.3389/fdgth.2022.1007784
33. Seyhan AA, Carini C. Are innovation and new technologies in precision medicine paving a new era in patients centric care?. *J Transl Med*. 2019; 17(1): 114. doi: 10.1186/s12967-019-1864-9
34. Davidson L, Boland MR. Towards deep phenotyping pregnancy: a systematic review on artificial intelligence and machine learning methods to improve pregnancy outcomes. *Brief Bioinform*. 2021; 22(5): bbba369. doi: 10.1093/bib/bbaa369
35. Weng C, Shah NH, Hripcsak G. Deep phenotyping: embracing complexity and temporality-towards scalability, portability, and interoperability. *J Biomed Inform*. 2020; 105: 103433. doi: 10.1016/j.jbi.2020.103433
36. Subbiah, V. The next generation of evidence-based medicine. *Nat Med*. 2023; 29: 49–58. doi: 10.1038/s41591-022-02160-z
37. Acosta JN, Falcone GJ, Rajpurkar P, Topol EJ. Multimodal biomedical AI. *Nat Med*. 2022; 28(9): 1773–84. doi: 10.1038/s41591-022-01981-2
38. Webster, K. A circular economy is about the economy. *Circ Econ Sust*. 2021; 1: 115–26. doi: 10.1007/s43615-021-00034-z
39. Guo C, Ashrafian H, Ghafur S, Fontana G, Gardner C, Prime M. Challenges for the evaluation of digital health solutions—A call for innovative evidence generation approaches. *npj Digit Med*. 2020; 3: 110. doi: 10.1038/s41746-020-00314-2
40. Gomes M, Murray E, Raftery J. Economic evaluation of digital health interventions: Methodological issues and recommendations for practice. *Pharmacoeconomics*. 2022; 40(4): 367–78. doi: 10.1007/s40273-022-01130-0
41. Artificial Intelligence Index Report. Stanford Institute for human-centered AI, Stanford University. 2022. Available from https://aiindex.stanford.edu/wp-content/uploads/2022/03/2022-AI-Index-Report_Master.pdf [cited 1 February 2023].
42. Brent Mittelstadt. The impact of artificial intelligence on the doctor-patient relationship. Research at the Oxford Internet Institute, University of Oxford, United Kingdom Commissioned by the Council of Europe Steering Committee for Human rights in the fields of Biomedicine and Health (CDBIO). 2021. Available from <https://rm.coe.int/inf-2022-5-report-impact-of-ai-on-doctor-patient-relations-e/1680a68859> [cited 1 February 2023].
43. Day S, Shah V, Kaganoff S, Powelson S, Mathews SC. Assessing the clinical robustness of digital health startups: cross-sectional observational analysis. *J Med Internet Res*. 2022; 24(6): e37677. doi: 10.2196/37677
44. Bringing the Benefits of Genome Sequencing to the World. Public policy projects, Global Insights. 2021. Available from: <https://publicpolicyprojects.com/policy/> [cited 1 February 2023].
45. Koutsouleris N, Hauser TU, Skvortsova V, De Choudhury M. From promise to practice: towards the realisation of AI-informed mental health care. *Lancet Digit Health*. 2022; 4(11): E829–40. doi: 10.1016/s2589-7500(22)00153-4
46. Lemmen C, Woopen C, Stock S. Systems medicine 2030: A Delphi study on implementation in the German healthcare system. *Health Policy*. 2021; 125(1): 104–14. doi: 10.1016/j.healthpol.2020.11.010

47. Abdelhalim H, Berber A, Lodi M, Jain R, Nair A, Pappu A, et al. Artificial Intelligence, healthcare, clinical genomics, and pharmacogenomics approaches in precision medicine. *Front Genet.* 2022; 13: 929736. doi: 10.3389/fgene.2022.929736
48. Tape, TG. Coherence and correspondence in medicine. *Judgm Decis Mak.* 2009; 4(2): 134–40. doi: 10.1017/S1930297500002564
49. Eliza Strickland. 6 reactions to the White House's AI Bill of Rights The nonbinding principles are being both celebrated and vilified. *IEEE spectrum* 14 October 2022. Available from: <https://spectrum.ieee.org/white-house-ai> [cited 1 February 2023].
50. Afolabi O, Parsekar K, Sibson L, Patel A, Fordham R. Cost effectiveness analysis of the East of England stroke telemedicine service. *J Stroke Cerebrovasc Dis.* 2023; 32(4): 106939. doi: 10.1016/j.jstrokecerebrovasdis.2022.106939
51. Wang SV, Sreedhara SK, Schneeweiss S. Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions. *Nat Commun.* 2022; 13(1): 5126. doi: 10.1038/s41467-022-32310-3
52. Essén A, Stern AD, Hase CB, Car J, Greaves F, Paparova D, et al. Health app policy: international comparison of nine countries' approaches. *npj Digit Med.* 2022; 5(1): 31. doi: 10.1038/s41746-022-00573-1
53. Diao JA, Venkatesh KP, Raza MM, Kvedar JC. Multinational landscape of health app policy: toward regulatory consensus on digital health. *npj Digit Med.* 2022; 5(1): 61. doi: 10.1038/s41746-022-00604-x
54. Neal D, Engelsma T, Tan J, Craven MP, Marcilly R, Peute L, et al. Limitations of the new ISO standard for health and wellness apps. *Lancet Digit Health.* 2022; 4(2): e80-2. doi: 10.1016/s2589-7500(21)00273-9
55. Maliha G, Gerke S, Cohen IG, Parikh RB. Artificial Intelligence and liability in medicine: balancing safety and innovation. *Milbank Q.* 2021; 99(3): 629-47. doi: 10.1111/1468-0009.12504
56. Sharkey CM. & Fodouop KM. AI and the regulatory paradigm shift at the FDA. *72 Duke Law J.* 2022: 86–112. Available from: https://scholarship.law.duke.edu/cgi/viewcontent.cgi?article=1100&context=dlj_online [cited 1 February 2023].
57. Richardson S, Lawrence K, Schoenthaler AM, Mann D. A framework for digital health equity. *npj Digit Med.* 2022; 5(1): 119. doi: 10.1038/s41746-022-00663-0
58. Kaihlanen AM, Virtanen L, Buchert U, Safarov N, Valkonen P, Hietapakka L, et al. Towards digital health equity – A qualitative study of the challenges experienced by vulnerable groups in using digital health services in the COVID-19 era. *BMC Health Serv Res.* 2022; 22: 188. doi: 10.1186/s12913-022-07584-4
59. Gonzales A, Guruswamy G, Smith SR. Synthetic data in health care: A narrative review. *PLOS Digit Health.* 2023 Jan 6;2(1): e0000082. doi: 10.1371/journal.pdig.0000082. PMID: 36812604; PMCID: PMC9931305.
60. Reiner Benaim A, Almog R, Gorelik Y, Hochberg I, Nassar L, Mashiach T, et al. Analyzing medical research results based on synthetic data and their relation to real data results: systematic comparison from five observational studies. *JMIR Med Inform.* 2020; 8(2): e16492. doi: 10.2196/16492
61. Kokosi T, Harron K. Synthetic data in medical research. *BMJ Medicine.* 2022; 1: e000167. doi: 10.1136/bmjmed-2022-000167
62. Ishii-Rousseau JE, Seino S, Ebner DK, Vareth M, Po MJ, Celi LA. The 'Ecosystem as a Service (EaaS)' approach to advance clinical artificial intelligence (cAI). *PLOS Digit Health.* 2022; 1(2): e0000011. doi: 10.1371/journal.pdig.0000011
63. Wang SV, Sreedhara SK, Schneeweiss S. REPEAT initiative. Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions. *Nat Commun.* 2022; 13(1): 5126. doi: 10.1038/s41467-022-32310-3
64. Rudrapatna VA, Butte AJ. Opportunities and challenges in using real-world data for health care. *J Clin Invest.* 2020; 130(2): 565–74. doi: 10.1172/JCI129197
65. Regulation of the European Parliament and of the Council laying down harmonised rules on Artificial Intelligence (Artificial Intelligence Act) and amending certain Union Legislative Acts. European Commission, Brussels, 21.4.2021, COM(2021) 206 final 2021/0106 (COD). Available from: <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52021PC0206> [cited 1 February 2023]
66. Why health-care services are in chaos everywhere. *The Economist*, 15 January 2023. Available from: <https://www.economist.com/finance-and-economics/2023/01/15/why-health-care-services-are-in-chaos-everywhere> [cited 1 February 2023]
67. Siegler JE, Patel NN, Dine CJ. Prioritizing paperwork over patient care: Why can't we do both? *J Grad Med Educ.* 2015; 7(1): 16–8. doi: 10.4300/JGME-D-14-00494.1
68. Doctors wasting over two-thirds of their time doing paperwork. *Forbes, Innovation in Healthcare.* 2016. Available from: <https://www.forbes.com/sites/brucelee/2016/09/07/doctors-wasting-over-two-thirds-of-their-time-doing-paperwork/> [cited 1 February 2023]
69. Field RI. Why is health care regulation so complex? *P T.* 2008; 33(10): 607-8.
70. Braithwaite J. Changing how we think about healthcare improvement. *BMJ.* 2018; 361: k2014. doi: 10.1136/bmj.k2014
71. Hudson CC, Gauvin S, Tabanfar R, Poffenroth AM, Lee JS, O'Riordan AL. Promotion of role clarification in the health care team challenge. *J Interprof Care.* 2017;31(3):401–3. doi: 10.1080/13561820.2016.1258393
72. Ly O, Sibbald SL, Verma JY, Rocker GM. Exploring role clarity in interorganizational spread and scale-up initiatives: the 'IN-SPIRED' COPD collaborative. *BMC Health Serv Res.* 2018; 18: 680. doi: 10.1186/s12913-018-3474-2
73. Patel RS, Bachu R, Adikey A, Malik M, Shah M. Factors related to physician burnout and its consequences: a review. *Behav Sci (Basel).* 2018; 8: 98. doi: 10.3390/bs8110098.30366419
74. Gardner RL, Cooper E, Haskell J. Physician stress and burnout: the impact of health information technology. *J Am Med Inform Assoc.* 2019; 26: 106–114. doi: 10.1093/jamia/ocy145.30517663
75. Berbis MA, McClintock DS, Bychkov A, Van der Laak J, Pantanowitz L, Lennertz JK, et al. Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade. *EBioMedicine.* 2023; 88: 104427. doi: 10.1016/j.ebiom.2022.104427
76. 'Practicing at the top of your license' and the 'Great' American healthcare labor arbitrage. *Forbes, Innovation in Healthcare.* 2022. Available from: <https://www.forbes.com/sites/sachin-jain/2022/04/04/the-great-american-healthcare-labor-arbitrage/> [cited 1 February 2023].
77. Subbe C, Barach P. Impact of electronic health records on pre-defined safety outcomes in patients admitted to hospital. A scoping review. *BMJ Open.* 2011; 11: e047446.
78. Califf RM. Now is the time to fix the evidence generation system. *Clinical Trials.* 2023; 17407745221147689. doi: 10.1177/17407745221147689
79. Dlima S, Shevade S, Menezes S, Ganju A. Digital phenotyping in health using machine learning approaches: scoping review. *JMIR Bioinform Biotech.* 2022; 3(1): e39618. doi: 10.2196/39618
80. Kanazawa N, Iijima H, Fushimi K. In-hospital cardiac rehabilitation and clinical outcomes in patients with acute myocardial

- infarction after percutaneous coronary intervention: a retrospective cohort study. *BMJ Open*. 2020; 10(9): e039096. doi: 10.1136/bmjopen-2020-039096
81. Bruce CR, Harrison P, Nisar T, Giammattei C, Tan NM, Bliven C, et al. Assessing the impact of patient-facing mobile health technology on patient outcomes: retrospective observational cohort study. *JMIR Mhealth Uhealth*. 2020; 8(6): e19333. doi: 10.2196/19333
 82. Parretti C, Tartaglia R, La Regina M, Venneri F, Sbrana G, Mandò M, et al. Improved FMEA methods for proactive health care risk assessment of the effectiveness and efficiency of COVID-19 remote patient telemonitoring. *Am J Med Qual*. 2022; 37(6): 535–44. doi: 10.1097/JMQ.0000000000000089
 83. Hartl D, De Luca V, Kostikova A, Laramie J, Kennedy S, Ferrero E, et al. Translational precision medicine: an industry perspective. *J Transl Med*. 2021; 19: 245. doi: 10.1186/s12967-021-02910-6

Copyright Ownership: This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, adapt, enhance this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0>.